Safety and Immunogenicity of Heterologous Prime-Boost with the Candidate Malaria Vaccines AdCh63 ME-TRAP and MVA ME- TRAP in Healthy Adults in a Malaria Endemic Area

niversity of Oxford0 个研究点目标入组 30 人开始时间: 2009年12月3日最近更新: 2023年5月29日

适应症

试验速览

暂无简介。

•·Clinically significant history of the following conditions; skin disorder (eczema, etc.), allergy, symptomatic immunodeficiency, cardiovascular disease, respiratory disease, endocrine disorder, liver disease, renal disease, gastrointestinal disease, neurological illness.
•·History of splenectomy
•·Haemoglobin less than 9.0 g/dl
•·Clinically significant abnormalities of laboratory screening tests (full blood count, ALT, creatinine levels, urine dipstick examination for blood and protein).
•·Blood transfusion within one month of the beginning of the study
•·History of vaccination with previous experimental malaria vaccines
•·Administration of any other vaccine or immunoglobulin within two weeks before vaccination.
•·Current participation in another clinical trial, or within 12 weeks of this study
•·Any other finding which in the opinion of the investigators would increase the risk of an adverse outcome from participation in the trial.
•·Likelihood of travel away from the study area
•·HIV positive.
•·History of contact dermatitis (due to the use of a potentially irritant disinfectant that may be present in trace amounts in the AdCh63 ME-TRAP vaccine)

发起方